Cited by 1,132Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchInflammatory mediators and NSAID effects

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Risk of Alzheimer's disease and duration of NSAID use

Open access

Stewart, Walter F., Kawas, Claudia, Corrada, Maria, Metter, E. Jeffrey·1997·Neurology

DOI 10.1212/wnl.48.3.626

Open this paper in CoChat — free account Open PDF

Abstract

In a longitudinal study of 1,686 participants in the Baltimore Longitudinal Study of Aging, we examined whether the risk of Alzheimer's disease (AD) was reduced among reported users of aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). In addition, we examined use of acetaminophen, a pain-relief medication with little or no anti-inflammatory activity, to assess the specificity of the association between AD risk and self-reported medications. Information on use of medications was collected during each biennial examination between 1980 and 1995. The relative risk (RR) for AD decreased with increasing duration of NSAID use. Among those with 2 or more years of reported NSAID use, the RR was 0.40 (95% confidence interval [CI]: 0.19-0.84) compared with 0.65 (95% CI: 0.33-1.29) for those with less than 2 years of NSAID use. The overall RR for AD among aspirin users was 0.74 (95% CI: 0.46-1.18), and no trend of decreasing risk of AD was observed with increasing duration of aspirin use. No association was found between AD risk and use of acetaminophen (RR = 1.35; 95% CI: 0.79-2.30), and there was no trend of decreasing risk with increasing duration of use. These findings are consistent with evidence from cross-sectional studies indicating protection against AD risk among NSAID users and with evidence suggesting that one stage of the pathophysiology leading to AD is characterized by an inflammatory process.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/wnl.48.3.626

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Boston Naming Test
Kaplan, E., Goodglass, H., Weıntraub, S., & Segal, O. (2001) · Medical Entomology and Zoology · Cited by 4,378
Bayes Estimates for the Linear Model
Lindley, D. V., & Smith, A. F. M. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00885.x · Cited by 2,025
Normal Human Aging: The Baltimore Longitudinal Study on Aging
Shock, N. W., Greulich, R. C., Costa, P. T., Andres, R., Lakatta, E. G., Arenberg, D., & Tobin, J. D. (1984) · University Libraries (University of Maryland) · doi:10.13016/sclw-iccq · Cited by 757
Inverse association of anti‐inflammatory treatments and Alzheimer's disease
Breitner, J. C. S., Gau, B. A., Welsh-Bohmer, K. A., Plassman, B. L., McDonald, W. M., Helms, M. J., & Anthony, J. C. (1994) · Neurology · doi:10.1212/wnl.44.2.227 · Cited by 569
Activation of the classical complement pathway in brain tissue of Alzheimer patients
McGeer, P. L., Akiyama, H., Itagaki, S., & McGeer, E. G. (1989) · Neuroscience Letters · doi:10.1016/0304-3940(89)90843-4 · Cited by 383
Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes.
Stremmel, W., Strohmeyer, G. W., Borchard, F., Kochwa, S., & Berk, P. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.1.4 · Cited by 350
A Population-Based Study of the Risk of Recurrence of Birth Defects
Lie, R. T., Wilcox, A. J., & Skjærven, R. (1994) · New England Journal of Medicine · doi:10.1056/nejm199407073310101 · Cited by 164
Social adjustment and psychopathology among formerly hospitalized and non-hospitalized mothers—I. Development of the social role adjustment instrument
Cohler, B. J., ROBBINS, D. M., Hartman, C. R., Shader, R. I., Grunebaum, H. U., Gallant, D. H., & Weiss, J. L. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90017-5 · Cited by 132
The need for multiple time points in aging studies
Coleman, P. A., Finch, C. E., & Joseph, J. A. (1990) · Neurobiology of Aging · doi:10.1016/0197-4580(90)90055-5 · Cited by 66

Show all 16 references

Research works printed but not linked: 16

Altstiel L, Sperber K. Cytokines in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1991;15:481-495.
Eikelenboom P, Stam FC. Immunoglobulins and complement factors in senile plaques: an immunohistochemical study. Acta Neuropathol (Berl) 1982;57:239-252.
Anonymous. The Canadian Study of Health and Aging: Risk factors for Alzheimer's disease in Canada. Neurology 1994;44:2073-2080.
Lucca U, Tettamanti M, Forloni G, Spagnoli A. Nonsteroidal antiinflammatory drug use in Alzheimer's disease. Biol Psychiatry 1994;36:854-856.
Andersen K, Launer LJ, Ott A, Hoes AW, Breteler MMB, Hofman A. Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease? Neurology 1995;45:1441-1445.
Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and of senile changes in the cerebral gray matter of elderly subjects. Br J Psychiatry 1968;114:797-811.
Benton AL. Differential behavioral effects in frontal lobe disease. Neuropsychologia 1968;6:53-60.
Rouleau I, Salmon DP, Butters N, Kennedy C, McGuire K. Quantitative and qualitative analyses of clock drawings in Alzheimer's and Huntington's disease. Brain Cogn 1992;18:70-87.
Morris JC, Mohs R, Rogers H, Fillenbaum G, Heyman A. Consortium to establish a Registry for Alzheimer's Disease (CERAD): clinical and neuropsychological assessment of Alzheimer's disease. Psychopharmacol Bull 1988;24:641-652.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
Pfeffer RI, Kurosaki TT, Harrah CH, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982;37:323-329.
Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence using the New Adult Reading Test. Cortex 1978;14:234-244.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
Checkoway H Pearce NE Crawford-Brown DJ. Research methods in occupational epidemiology monographs in epidemiology and biostatistics vol 13. New York: Oxford University Press 1989:153-155.
Aspirin Myocardial Infarction Study Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980;243:661-669.
Paulas HE. Nonsteroidal anti-inflammatory drugs. In: Kelley WN Harris ED Ruddy S Sledge CB eds. A textbook of rheumatology. Philadelphia: WB Saunders 1989.

Sorted by citations

Items 601–700 of 1,000

Synthesis and biological evaluation of 1,3,4-triaryl-3-pyrrolin-2-ones, a new class of selective cyclooxygenase-2 inhibitors
Bosch, J., Roca, T., Catena, J., Llorens, O., Pérez, J. J., Lagunas, C., Fernández, A. G., Miquel, I., Fernandez‐Serrat, A., & Farrerons, C. (2000) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)00329-2 · Cited by 29
Is there a Future for Cyclo-Oxygenase Inhibitors in Alzheimer???s Disease?
Ho, L., Qin, W., Stetka, B., & Pasinetti, G. M. (2006) · CNS Drugs · doi:10.2165/00023210-200620020-00001 · Cited by 29
Vascular nitric oxide may lessen Alzheimer's risk
McCarty, M. F. (1998) · Medical Hypotheses · doi:10.1016/s0306-9877(98)90066-4 · Cited by 30
Nonsteroidal Anti‐Inflammatory Drugs Increase Tumor Necrosis Factor Production in the Periphery but Not in the Central Nervous System in Mice and Rats
Sacco, S., Agnello, D., Sottocorno, M., Lozza, G., Monopoli, A., Villa, P., & Ghezzi, P. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052063.x · Cited by 29
Identification and modification of amyloid-independent phenotypes of APOE4 mice
DiBattista, A. M., Dumanis, S. B., Newman, J., & Rebeck, G. W. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.04.014 · Cited by 28
Alzheimer’s Disease Treatment: The Search for a Breakthrough
Reiss, A. B., Muhieddine, D., Jacob, B., Mesbah, M., Pinkhasov, A., Gomolin, I. H., Stecker, M. M., Wısnıewskı, T., & Leon, J. D. (2023) · Medicina · doi:10.3390/medicina59061084 · Cited by 31
Effect of General Anesthetics on Amyloid Precursor Protein and mRNA Levels in the Rat Brain
Palotás, M., Palotás, A., Bjelik, A., Pákáski, M., Hugyecz, M., Janka, Z., & Kalman, J. L. (2005) · Neurochemical Research · doi:10.1007/s11064-005-6786-7 · Cited by 28
A Link Between Nerve Growth Factor Metabolic Deregulation and Amyloid-β-Driven Inflammation in Down Syndrome
Iulita, M. F., Caraci, F., & Cuello, A. C. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666160321104916 · Cited by 28
Inflammatory Cyclooxygenase Activity and PGE2 Signaling in Models of Alzheimer’s Disease
Johansson, J. U., Woodling, N. S., Shi, J., & Andreasson, K. I. (2015) · Current Immunology Reviews · doi:10.2174/1573395511666150707181414 · Cited by 28
Regulation of cyclo-oxygenase-2
Stack, E., & DuBois, R. N. (2001) · Best Practice & Research Clinical Gastroenterology · doi:10.1053/bega.2001.0235 · Cited by 28
Clinically tested drugs for Alzheimer?s disease
McGeer, E. G., & McGeer, P. L. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.7.1143 · Cited by 28
Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in β-amyloid protein-stimulated J774 cells
Ogawa, O., Umegaki, H., Sumi, D., Hayashi, T., Nakamura, A., Thakur, N. K., Yoshimura, J., Endo, H., & Iguchi, A. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00721-4 · Cited by 28
Aspirin: past, present and future
Elwood, P. C. (2001) · Clinical Medicine · doi:10.7861/clinmedicine.1-2-132 · Cited by 28
Cholesterol independent effect of LXR agonist TO‐901317 on gamma‐secretase
Czech, C., Burns, M. P., Vardanian, L., Augustin, A., Jacobsen, H., Baumann, K., & Rebeck, G. W. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04467.x · Cited by 27
Mean Daily Dosage of Aspirin and the Risk of Incident Alzheimer’s Dementia in Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study in Taiwan
Chang, C.-W., Horng, J., Hsu, C.-C., & Chen, J.-M. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9027484 · Cited by 27
Treatment of mild cognitive impairment: rationale, present and future strategies
Jelić, V., & Winblad, B. G. (2003) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.107.s179.12.x · Cited by 27
Processing of Amyloid Precursor Protein as a Biochemical Link Between Atherosclerosis and Alzheimers Disease
Jans, D. A., Martinet, W., van de Parre, T. J. L., Herman, A. G., Bult, H., Kockx, M. M., & Meyer, G. R. Y. D. (2006) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/187152906776092695 · Cited by 27
Down Syndrome
Capone, G. T. (2004) · Infants & Young Children · doi:10.1097/00001163-200401000-00007 · Cited by 29
A Case-Control Analysis of Nonsteroidal Anti-Inflammatory Drugs and Alzheimer’s Disease: Are They Protective?
Wolfson, C. M., Perrault, A., Moride, Y., Esdaile, J. M., Abenhaim, L., & Momoli, F. (2002) · Neuroepidemiology · doi:10.1159/000048621 · Cited by 27
Anti-inflammatory substances – a new therapeutic option in Alzheimer's disease
Hüll, M. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01339-2 · Cited by 27
Synthesis and pharmacochemical study of novel polyfunctional molecules combining anti-inflammatory, antioxidant, and hypocholesterolemic properties
Doulgkeris, C. M., Galanakis, D., Kourounakis, A. P., Tsiakitzis, K. C., Gavalas, A. M., Eleftheriou, P. T., Victoratos, P., Rekka, E. A., & Kourounakis, P. N. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.11.027 · Cited by 27
Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using Catalyst
Chopra, M., Gupta, R., Gupta, S., & Saluja, D. (2008) · Journal of Molecular Modeling · doi:10.1007/s00894-008-0350-8 · Cited by 26
Using a symptom-triggered approach to manage patients in acute alcohol withdrawal.
McKay, A. E., Koranda, A., & Axen, D. M. (2004) · PubMed · Cited by 26
Prevention strategies for Alzheimer’s disease
Gauthier, S. G., Wu, L., Rosa‐Neto, P., & Jia, J. (2012) · Translational Neurodegeneration · doi:10.1186/2047-9158-1-13 · Cited by 31
Coenzyme Q10 attenuated β-amyloid25–35–induced inflammatory responses in PC12 cells through regulation of the NF–κB signaling pathway
Li, L., Xu, D., Lin, J., Zhang, D., Wang, G.-H., Sui, L., Ding, H., & Du, J. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.04.014 · Cited by 26
Pain and Alzheimer’s Disease
Pickering, G. P., Eschalier, A., & Dubray, C. (2000) · Gerontology · doi:10.1159/000022166 · Cited by 26
Cyclooxygenase 2 selective inhibitors: Panacea or flash in the pan?
Beejay, U., & Wolfe, M. M. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70358-6 · Cited by 26
ALZHEIMER'S DISEASE AND VASCULAR FACTORS: FACTS AND THEORIES
Pansari, K., Gupta, A., & Thomas, P. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11233.x · Cited by 27
Pharmacology and Toxicology of Ibuprofen
Rainsford, K. D. (2015) · doi:10.1002/9781118743614.ch5 · Cited by 26
Mechanism of action of anti-inflammatory drugs: an overview
Vane, J. R., & Botting, R. M. (1998) · Springer eBooks · doi:10.1007/978-94-011-4872-6_1 · Cited by 25
Therapy of Alzheimer's disease: an update.
Upadhyaya, P., Seth, V., & Ahmad, M. (2010) · African Journal of Pharmacy and Pharmacology · doi:10.5897/ajpp.9000277 · Cited by 24
NSAID Use and Incident Cognitive Impairment in a Population-based Cohort
Wichmann, M. A., Cruickshanks, K. J., Carlsson, C. M., Chappell, R. J., Fischer, M., Klein, R., Klein, R., & Schubert, C. R. (2015) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000098 · Cited by 26
Alzheimer's disease: epidemiology
Mayeux, R. P. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01218-3 · Cited by 25
Inflammation as a Therapeutic Target for Various Deadly Disorders: A Review
Dhingra, A. K., & Chopra, B. (2019) · Current Drug Targets · doi:10.2174/1389450120666191204154115 · Cited by 25
Blockade of chloride intracellular ion channel 1 stimulates Aβ phagocytosis
Paradisi, S., Matteucci, A., Fabrizi, C., Denti, M. A., Abeti, R., Breit, S. N., Malchiodi‐Albedi, F., & Mazzanti, M. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21693 · Cited by 25
Inflammatory processes and Alzheimer’s disease
Walsh, S. P., & Aisen, P. S. S. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.5.793 · Cited by 25
Nonsteroidal anti-inflammatory drugs in Parkinson’s disease: possible involvement of quinone formation
Asanuma, M., & Miyazaki, I. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1313 · Cited by 28
Doubt and certainty about nonsteroidal anti-inflammatory drugs in the year 2000: a multidisciplinary expert statement
Hawkey, C. J., & Lanas, A. I. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00651-3 · Cited by 26
Are vascular factors involved in Alzheimer’s disease? Facts and theories
Iorio, A. D., Zito, M., Lupinetti, M. C., & Abate, G. (1999) · Aging Clinical and Experimental Research · doi:10.1007/bf03339811 · Cited by 25
Recent advances: Geriatric medicine
Pahor, M., & Applegate, W. B. (1997) · BMJ · doi:10.1136/bmj.315.7115.1071 · Cited by 25
A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders
Kopp, K. O., Greer, M. E., Glotfelty, E. J., Hsueh, S., Tweedie, D., Kim, D. S., Reale, M., Vargesson, N., & Greig, N. H. (2023) · Biomolecules · doi:10.3390/biom13050747 · Cited by 26
Extreme Stability of Chitotriosidase in Cerebrospinal Fluid makes it a Suitable Marker for Microglial Activation in Clinical Trials
Olsson, B., Malmeström, C., Basun, H., Annas, P., Höglund, K., Lannfelt, L., Andreasen, N., Zetterberg, H., & Blennow, K. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-120931 · Cited by 29
Luminescent complexes of terbium ion for molecular recognition of ibuprofen
Selivanova, N. M., Vasilieva, K., & Galyametdinov, Y. G. (2013) · Luminescence · doi:10.1002/bio.2526 · Cited by 25
Neuroimmunomodulation by calcineurin in aging and Alzheimer's disease.
Reese, L. C., & Taglialatela, G. (2010) · Europe PMC (PubMed Central) · Cited by 26
Inflammation in Alzheimer’s disease
Heneka, M. T. (2006) · Clinical Neuroscience Research · doi:10.1016/j.cnr.2006.09.005 · Cited by 25
Computational studies of COX-2 inhibitors: 3D-QSAR and docking
Kim, H. J., Chae, C. H., Yi, K. Y., Park, K.-L., & Yoo, S. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.01.027 · Cited by 24
Dysfunctional Sensory Modalities, Locus Coeruleus, and Basal Forebrain: Early Determinants that Promote Neuropathogenesis of Cognitive and Memory Decline and Alzheimer’s Disease
Daulatzai, M. A. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9643-3 · Cited by 27
Potential novel targets for Alzheimer pharmacotherapy: I. Secretases
Maiorini, A. F., Gaunt, M., Jacobsen, T., McKay, A. E., Waldman, L., & Raffa, R. B. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00415.x · Cited by 24
Alzheimer’s disease, brain immune privilege and memory: a hypothesis
Arshavsky, Y. I. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0524-4 · Cited by 23
Human leucocyte antigen-A2 increases risk of Alzheimer's disease but does not affect age of onset in a Scottish population
Harris, J. M., Cumming, A., Craddock, N. J., Clair, D. S., & Lendon, C. L. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01539-1 · Cited by 24
Role of Oxidative Stress and Neuroinflammation in the Etiology of Alzheimer’s Disease: Therapeutic Options
Weinstock, M. (2025) · Antioxidants · doi:10.3390/antiox14070769 · Cited by 25
Patterns of anti‐inflammatory drug use and risk of dementia: a matched case–control study
Dregan, A., Chowienczyk, P., & Armstrong, D. (2015) · European Journal of Neurology · doi:10.1111/ene.12774 · Cited by 23
CNS Adverse Effects of Nonsteroidal Anti-Inflammatory Drugs
Morgan, A., & Clark, D. W. J. (1998) · CNS Drugs · doi:10.2165/00023210-199809040-00004 · Cited by 23
S- but not R-enantiomers of flurbiprofen and ibuprofen reduce human microglial and THP-1 cell neurotoxicity
Klegeris, A., Maguire, J. A., & McGeer, P. L. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2004.04.001 · Cited by 23
Is it All Said for NSAIDs in Alzheimer’s Disease? Role of Mitochondrial Calcium Uptake
Sanz‐Blasco, S., Calvo-Rodríguez, M., Caballero, E., García-Durillo, M., Núñez, L., & Villalobos, C. (2017) · Current Alzheimer Research · doi:10.2174/1567205015666171227154016 · Cited by 24
Prospective longitudinal evaluation of cytokines in mild cognitive impairment due to AD and Lewy body disease
Thomas, A. J., Hamilton, C. A., Donaghy, P. C., Martin-Ruiz, C. M., Morris, C. M., Barnett, N., Olsen, K., Taylor, J., & O'Brien, J. T. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5365 · Cited by 23
Risk of Alzheimer's disease and duration of NSAID use
Delanty, N., & Vaughan, C. J. (1998) · Neurology · doi:10.1212/wnl.51.2.652 · Cited by 23
Characterisation of amyloid-induced inflammatory responses in the rat retina
Howlett, D. R., Bate, S. T., Collier, S., Lawman, A. J., Chapman, T. D., Ashmeade, T. E., Marshall, I. C. B., Anderson, P. J., Philpott, K. L., Richardson, J. C., et al. (2011) · Experimental Brain Research · doi:10.1007/s00221-011-2819-4 · Cited by 22
Is Alzheimer’s Disease Autoimmune Inflammation of the Brain That Can be Treated With Nasal Nonsteroidal Anti-Inflammatory Drugs?
Lehrer, S. P., & Rheinstein, P. H. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514545478 · Cited by 22
Aspirin modulates LPS-induced nitric oxide release in rat glial cells
Marchini, C., Angeletti, M., Eleuteri, A. M., Fedeli, A., & Fioretti, E. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.02.002 · Cited by 22
Chymotrypsin‐like proteases contribute to human monocytic THP‐1 cell as well as human microglial neurotoxicity
Klegeris, A., & McGeer, P. L. (2005) · Glia · doi:10.1002/glia.20186 · Cited by 22
Medication use to manage comorbidities for people with dementia: a systematic review
Page, A. T., Etherton‐Beer, C., Seubert, L., Clark, V., Hill, X., King, S., & Clifford, R. M. (2018) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1403 · Cited by 23
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Hake, A. (2001) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.68.7.608 · Cited by 22
Chronic intracerebroventricular infusion of lipopolysaccharide: effects of ibuprofen treatment and behavioural and histopathological correlates
Richardson, R. L., Kim, E.-M., Gardiner, T. A., & O‘Hare, E. (2005) · Behavioural Pharmacology · doi:10.1097/01.fbp.0000179278.03868.96 · Cited by 22
Localization and Distribution of Cyclooxygenase-2 in Brain Tissue by Immunohistochemistry
O’Banion, M. K., & Olschowka, J. A. (2003) · Humana Press eBooks · doi:10.1385/1-59259-263-5:55 · Cited by 22
Alzheimer's disease: Its diagnosis and pathogenesis
Kril, J. J., & Halliday, G. M. (2001) · International review of neurobiology · doi:10.1016/s0074-7742(01)48016-0 · Cited by 22
Brain Damage - Bridging Between Basic Research and Clinics
González-Quevedo, A. (2012) · InTech eBooks · doi:10.5772/2174 · Cited by 21
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 25
Epidemiology of Cognitive Aging and Alzheimer’s Disease: Contributions of the Cache County Utah Study of Memory, Health and Aging
Hayden, K. M., & Welsh-Bohmer, K. A. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_152 · Cited by 31
NO‐flurbiprofen reduces amyloid‐β, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade
Abdul‐Hay, S. O., Luo, J., Asghodom, R. T., & Thatcher, G. R. J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06353.x · Cited by 21
Insufficient Resolution Response in the Hippocampus of a Senescence-Accelerated Mouse Model — SAMP8
Wang, X., Puerta, E., Cedazo-Mı́nguez, Á., Hjorth, E., & Schultzberg, M. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0346-z · Cited by 21
The effects of aging, housing and ibuprofen treatment on brain neurochemistry in a triple transgene Alzheimer’s disease mouse model using magnetic resonance spectroscopy and imaging
Choi, J., Carreras, I., Aytan, N., Jenkins-Sahlin, E., Dedeoglu, A., & Jenkins, B. G. (2014) · Brain Research · doi:10.1016/j.brainres.2014.09.067 · Cited by 21
Curcumin Ameliorates the Reduction Effect of PGE2 on Fibrillar β-Amyloid Peptide (1-42)-Induced Microglial Phagocytosis through the Inhibition of EP2-PKA Signaling in N9 Microglial Cells
He, G., Luo, Z., Yang, J., Shen, T., Chen, Y., & Yang, X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147721 · Cited by 21
Preventive Effects of Tryptophan–Methionine Dipeptide on Neural Inflammation and Alzheimer’s Pathology
Ano, Y., Yoshino, Y., Uchida, K., & Nakayama, H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133206 · Cited by 21
Brain Arrhythmias Induced by Amyloid Beta and Inflammation: Involvement in Alzheimer’s Disease and Other Inflammation-related Pathologies
Peña‐Ortega, F. (2019) · Current Alzheimer Research · doi:10.2174/1567205017666191213162233 · Cited by 21
Las fronteras entre el envejecimiento cognitivo normal y la enfermedad de Alzheimer.: El concepto de deterioro cognitivo leve
Otero, J. L., & Scheitler, L. F. (2003) · Revista Médica del Uruguay · Cited by 20
No association between the HLA-A2 allele and Alzheimer disease
Small, G. W., Scott, W. K., Komo, S., Yamaoka, L. H., Farrer, L. A., Auerbach, S. H., Saunders, A. M., Roses, A. D., Haines, J. L., & Pericak‐Vance, M. A. (1999) · Neurogenetics · doi:10.1007/s100480050080 · Cited by 21
Present and prospective clinical therapeutic regimens for Alzheimer’s disease
Husain, M. M. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s2012 · Cited by 21
Neurocognitive Enhancement: Ethical Considerations for an Emerging Subspecialty
Bush, S. S. (2006) · Applied Neuropsychology · doi:10.1207/s15324826an1302_7 · Cited by 21
Effects of non-steroidal anti-inflammatory drugs on Aβ deposition in Aβ1–42 transgenic C. elegans
Morita, M., Osoda, K., Yamazaki, M., Shirai, F., Matsuoka, N., Arakawa, H., & Nishimura, S. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.002 · Cited by 21
Autoradiographical imaging of PPARγ agonist effects on PBR/TSPO binding in TASTPM mice
Roberts, J. C., Friel, S. L., Roman, S. A., Perren, M. J., Harper, A. J., Davis, J. B., Richardson, J. C., Virley, D. J., & Medhurst, A. D. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.01.002 · Cited by 23
Facilitatory effect of aspirin on glutamate release from rat hippocampal nerve terminals: Involvement of protein kinase C pathway
Wang, S. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.10.006 · Cited by 21
Morphological, biochemical and behaviouralchanges induced by neurotoxic and inflammatory insultsto the nucleus basalis
Casamenti, F., Prosperi, C., Scali, C., Giovannelli, L., & Pepeu, G. (1998) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(98)00080-x · Cited by 21
NO-Flurbiprofen Attenuates Excitotoxin-Induced Brain Inflammation, and Releases Nitric Oxide in the Brain
Prosperi, C., Scali, C., Pepeu, G., & Casamenti, F. (2001) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.86.230 · Cited by 21
Long‐Term Exposure to Non‐Steroidal Anti‐Inflammatory Medication in Relation to Dementia Risk
Hofe, I. V., Stricker, B. H. C., Ikram, M. A., Wolters, F. J., & Ikram, M. A. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.19411 · Cited by 23
Delivery of Polymeric Nanoparticles to Target Vascular Diseases
Agyare, E., & Kandimalla, K. K. (2014) · Journal of Biomolecular Research & Therapeutics · doi:10.4172/2167-7956.s1-001 · Cited by 20
The Role of Cardiovascular Risk Factors in Alzheimer's Disease
Ravona‐Springer, R., Davidson, M., & Noy, S. (2003) · CNS Spectrums · doi:10.1017/s109285290001926x · Cited by 20
Lychee Seed Fraction Inhibits Aβ(1-42)-Induced Neuroinflammation in BV-2 Cells via NF-κB Signaling Pathway
Zhao, Y., Zeng, Y., Wu, A., Yu, C., Tang, Y., Wang, X., Xiong, R., Chen, H., Wu, J., & Qin, D. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00380 · Cited by 20
When safeguarding goes wrong: Impact of oxidative stress on protein homeostasis in health and neurodegenerative disorders
Mesika, R., & Reichmann, D. (2018) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2018.11.001 · Cited by 20
COX-3: Uncertainties and controversies
Kam, P. C. A., & So, A. (2008) · Current Anaesthesia and Critical Care · doi:10.1016/j.cacc.2008.11.003 · Cited by 22
Anti-inflammatory agents in Alzheimer’s disease
Aisen, P. S. S. (2002) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-002-0066-6 · Cited by 20
Perspectives in clinical Alzheimer’s disease research and the development of antidementia drugs
Grundman, M., Corey‐Bloom, J., & Thal, L. J. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_23 · Cited by 20
Nickel(II)–meclofenamate complexes: Structure, in vitro and in silico DNA– and albumin–binding studies, antioxidant and anticholinergic activity
Barmpa, A., Geromichalos, G. D., Hatzidimitriou, A. G., & Psomas, G. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111507 · Cited by 19
Chronic ibuprofen treatment does not affect the secondary pathology in the thalamus or improve behavioral outcome in middle cerebral artery occlusion rats
Lipsanen, A., Hiltunen, M. O., & Jolkkonen, J. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.019 · Cited by 19
Preliminary Assessment of Cognitive Function in Older Adults by Clock Drawing, Box Copying and Narrative Writing
Paganini‐Hill, A., & Clark, L. J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000097097 · Cited by 19
Genetic Analysis of Interleukin-1A C(-889)T Polymorphism with Alzheimer Disease
Hu, J.-L., Li, G., Zhou, D., Zou, Y., Zhu, Z., Xu, R., Jiang, X., & Zeng, Y. (2008) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-008-9299-5 · Cited by 17
Pharmacokinetic and ulcerogenic studies of naproxen prodrugs designed for specific brain delivery
Sheha, M. M. (2012) · Archives of Pharmacal Research · doi:10.1007/s12272-012-0316-3 · Cited by 19
Predicting Alzheimer’s Disease in the Baltimore Longitudinal Study of Aging
Zonderman, A. B. (2005) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988705281863 · Cited by 19
Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex
Flanagan, M. E., Larson, E. B., Walker, R. L., Keene, C. D., Postupna, N. O., Cholerton, B., Sonnen, J. A., Dublin, S., Crane, P. K., & Montine, T. J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170414 · Cited by 20
Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study
de Craen, A. J. M., Gussekloo, J., Teng, Y. K. O., Macfarlane, P. W., & Westendorp, R. G. J. (2003) · BMJ · doi:10.1136/bmj.327.7407.131 · Cited by 19

Authors: Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J.
Affiliations: Johns Hopkins University (US)
ORCID: Stewart, Walter F.
Kawas, Claudia
Metter, E. Jeffrey
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-03
Volume: 48
Issue: 3
Pages: 626-632
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.48.3.626
OpenAlex: W2163110760
Cited by: 1,132
References: 16
Citations by year: 2026: 5 · 2025: 9 · 2024: 13 · 2023: 22 · 2022: 19 · 2021: 22 · 2020: 23 · 2019: 22 · 2018: 21 · 2017: 24 · 2016: 28 · 2015: 29 · 2014: 32 · 2013: 24 · 2012: 31
FWCI: 42.05
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders: American Academy of Neurology
National Institutes of Health
National Institute on Aging (R01AG008325, R01-AG08325)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
Keywords: Alzheimer's disease, nonsteroidal anti-inflammatory drugs, aspirin, paracetamol, medication use, neuroprotection, neuroinflammation
MeSH terms: Acetaminophen, Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Prospective Studies, Confidence Intervals, Risk Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of Alzheimer's disease and duration of NSAID use

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks